Drugs / predinisone
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06754267 | Dec 2024 → Dec 2025 overdue | precursor B-cell acute lymphoblastic leukemia | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07371923 Background | Nov 2025 → Feb 2028 expected | diffuse large B-cell lymphoma | Beijing Tongren Hospital | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05899725 Background | Apr 2023 → Mar 2025 | drug or radiation exposure-related interstitial lung disease | Peking Union Medical College Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | predinisone | “zanubrutinib combined with Pola-R-CHP regimen: zanubrutinib 160mg bid d1-d21/C1-C6; polatuzumab 1.8mg/kg d1/C1-C6; rituximab 375mg/㎡, iv, d1/C1-C6; cyclophosphamide 750mg/㎡,...” NCT07371923 ↗2“Initial dosage of corticosteroids is no less than predinisone 1mg/kg/d or other corticosteroids with equal equivalence” NCT05899725 ↗ |
| Route | Oral | “Predinisone for 3 weeks, oral” NCT06754267 ↗ |